Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "AstraZeneca"

353 News Found

FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
Drug Approval | June 02, 2026

FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG

First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death


AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26
News | June 01, 2026

AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26

While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications


AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial
Clinical Trials | May 30, 2026

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis


FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough
R&D | May 30, 2026

FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term


FDA delays AstraZeneca decision on camizestrant as regulators seek more data
Drug Approval | May 30, 2026

FDA delays AstraZeneca decision on camizestrant as regulators seek more data

The filing is backed by results from the pivotal SERENA-6 Phase III trial


AstraZeneca to showcase cancer pipeline push at ASCO 2026
R&D | May 25, 2026

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies


AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%
Clinical Trials | May 25, 2026

AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%

The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial


Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug
Drug Approval | May 19, 2026

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies


AstraZeneca launches K+ Connect initiative to strengthen hyperkalemia management
Healthcare | May 13, 2026

AstraZeneca launches K+ Connect initiative to strengthen hyperkalemia management

Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure


FDA advisory panel backs AstraZeneca prostate cancer combo in decisive vote
News | May 04, 2026

FDA advisory panel backs AstraZeneca prostate cancer combo in decisive vote

The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer